Ketamine modulates disrupted in schizophrenia-1/glycogen synthase kinase-3β interaction.
Frontiers in molecular neuroscience January 1, 2024 Jia-Ren Liu, Xiao Hui Han, Koichi Yuki et al. 4 citations
Ketamine, an anesthetic, reduces levels of the DISC1 protein in the brains of newborn rats, which is linked to increased activity of GSK-3β, an enzyme involved in cell signaling. This reduction corresponds to decreased axonal growth and increased cell death. Lithium, a GSK-3β antagonist, reverses these effects, suggesting a connection between DISC1 and ketamine-induced neurodegeneration.